Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
|
publications [2026/04/01 09:20] ramirez [2026] |
publications [2026/04/01 09:21] (current) ramirez [2025] |
||
|---|---|---|---|
| Line 39: | Line 39: | ||
| Stanley S, [[people:anacosta|Silva-Costa C]], [[people:jfsilva|Gomes-Silva J]], [[people:jmelocristino|Melo-Cristino J]], Malley R, [[people:ramirez|Ramirez M]]. 2025. <fc #0000FF>CC180 clade dynamics do not universally explain //Streptococcus pneumoniae// serotype 3 persistence post-vaccine: a global comparative population genomics study</fc>. Ebiomedicine 117:105781. [[https://www.ncbi.nlm.nih.gov/pubmed/40472804/|(PMID: 40472804)]] | Stanley S, [[people:anacosta|Silva-Costa C]], [[people:jfsilva|Gomes-Silva J]], [[people:jmelocristino|Melo-Cristino J]], Malley R, [[people:ramirez|Ramirez M]]. 2025. <fc #0000FF>CC180 clade dynamics do not universally explain //Streptococcus pneumoniae// serotype 3 persistence post-vaccine: a global comparative population genomics study</fc>. Ebiomedicine 117:105781. [[https://www.ncbi.nlm.nih.gov/pubmed/40472804/|(PMID: 40472804)]] | ||
| - | Carvalho BT, Meirinhos SV, Domingos GJ, Peixoto S, [[people:jmelocristino|Melo-Cristino J]]. 2025. <fc #0000FF>Unseen but unforgettable - refractive bacilli in the Gram stain of a muscular abscess</fc>. Eur J Clin Microbiol Infect Dis //In press// [[https://www.ncbi.nlm.nih.gov/pubmed/40307630/|(PMID: 40307630)]] | + | Carvalho BT, Meirinhos SV, Domingos GJ, Peixoto S, [[people:jmelocristino|Melo-Cristino J]]. 2025. <fc #0000FF>Unseen but unforgettable - refractive bacilli in the Gram stain of a muscular abscess</fc>. Eur J Clin Microbiol Infect Dis 44:1749-1752 [[https://www.ncbi.nlm.nih.gov/pubmed/40307630/|(PMID: 40307630)]] |
| Schnyder JL, de Jong HK, Bache EB, van Hest RM, Bélard S, Hanscheid T, Kremsner PG, Grobusch MP. 2025. <fc #0000FF>Which trial do we need? A randomised controlled study to compare the protective efficacy of early post-exposure discontinuation versus standard atovaquone-proguanil malaria prophylaxis in a human //Plasmodium falciparum// challenge model</fc>. Clin Microbiol Infect 31:1618–1622. [[https://www.ncbi.nlm.nih.gov/pubmed/40294866/|(PMID: 40294866)]] | Schnyder JL, de Jong HK, Bache EB, van Hest RM, Bélard S, Hanscheid T, Kremsner PG, Grobusch MP. 2025. <fc #0000FF>Which trial do we need? A randomised controlled study to compare the protective efficacy of early post-exposure discontinuation versus standard atovaquone-proguanil malaria prophylaxis in a human //Plasmodium falciparum// challenge model</fc>. Clin Microbiol Infect 31:1618–1622. [[https://www.ncbi.nlm.nih.gov/pubmed/40294866/|(PMID: 40294866)]] | ||